论文部分内容阅读
本文对全日本急性巨核细胞白血病(FAB-M7)病例进行了临床分析,计M726例,急性骨髓纤维化(AMF)6例。21例M7采用了以蒽环类抗生素、阿糖胞苷、6-巯基嘌呤为主的联合化疗,结果完全缓解(CR)率为47.6%(10/21)。治疗日始的中位数生存期,CR组为12个月,无效(NR)组为5个月,获得CR是延长生存期的重要因素。3例AMF亦采用了相似的治疗方案,但均NR。19例M7中有11例(58%)通过骨髓活检确诊为合并骨髓纤维化。经上述方案化疗,结果,合并纤维化者的R率为27%(3/11),无纤维化者的CR率为50%(2/4)。可见,M7伴有骨髓纤维
In this paper, clinical analysis of all cases of acute megakaryoblastic leukemia (FAB-M7) in Japan, including M726 cases, acute myelofibrosis (AMF) in 6 cases. Twenty-one of the 21 M7 patients treated with anthracycline, cytarabine and 6-mercaptopurine showed a complete response (CR) rate of 47.6% (10/21). The median median survival at the start of treatment was 12 months in the CR group and 5 months in the NR group, and CR was an important factor in prolonging survival. Three cases of AMF also used a similar treatment, but all NR. Eleven of the 19 M7 (58%) were diagnosed with myelofibrosis by a bone marrow biopsy. Chemotherapy with the above regimen resulted in an R rate of 27% (3/11) in those with fibrosis and 50% (2/4) in those without fibrosis. Can be seen, M7 accompanied by bone marrow fibers